NEW YORK (TheStreet) -- Shares of Atossa Genetics (ATOS) are down 8.5% to $1.72 on heavy trading volume after thehealthcare company, focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer, was said to faceliquidity issues, according to MarketsEmerging.com.

The site noted that in its latest 10-Q, Atossa states that it has sufficient resources to fund operations potentially only through Q1. "On a dubious note," Markets Emerging said, "the firm has apparently hired BDO USA as its accountant. BDO covered Robert Allen Stanford's $7B Ponzi scheme."

The company's stock had jumped31.5% perhaps, Markets Emerging continued, on an optimistic report issuedby Zacks Investment Research, after the company announced on December 19 that its subsidiary in Seattle, WA had begun pharmacogenetics testing as a service to physicians to assist them in prescribing drugs.

Exclusive Report: Jim Cramer's Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read more from the original source:
Atossa Genetics (ATOS) Stock Declines Today on Heavy Trading Volume

Comments are closed.